Stock·NYSE·Healthcare
Pfizer Inc. (PFE)
- Market cap
- $167.80B
- P/E
- 37.27
- Dividend yield
- 5.85%
- Street target
- $28.50median of 28 analysts
- 52-week range
- $23.62 $29.88
The short version
Where PFE stands today, in four lines, and what CleaRank Financial AI makes of it.
PFE at a glance
Pfizer Inc. (PFE): Hold, 52/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($27.90 and $26.54).
- Earnings PFE beat estimates in 8 of its last 8 quarters, yet fell the next day after 1 of those beats.
- Insiders Insiders sold $135K and bought $3.0M over the last 18 months.
- Valuation P/E of 37.3 against 31.9 for the Healthcare sector: broadly in line with peers (+17%).
Figures as of October 16, 2026.
CleaRank Financial AI
At $29.44, Pfizer Inc. (PFE) trades above its 50-day simple moving average of $27.90 and its 200-day simple moving average of $26.54, which confirms a firm uptrend over both intermediate and long horizons. The shares are also 6.50% above their 30.86 million average daily volume on the latest session of 32.87 million shares, a sign of active participation during the advance.
Against that, Wall Street forecasts revenue of $62.3B for the current year with 0.00% growth and $59.9B next year, a 4.00% decline, and analysts project next-year EPS growth of -2.6%. Insiders are net buyers with $3.0M in total purchases versus $135K in total sales, led by Chairman and CEO an insider, and the insider verdict is a moderate buy signal. The main risk is that the valuation has moved ahead of the consensus: the company's 5.01% return on equity and 6.80% net profit margin are thin for a 37x earnings multiple, and the 5-year past growth rate of -6.4% per year means the rally rests on near-term beats rather than a growth reacceleration.
Insiders are net buyers with $3.0M in total purchases versus $135K in total sales in recent filings.Only on CleaRank
Figures we compute ourselves from PFE's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $29.44 is 5.5% above the 50-day simple moving average of $27.90.Price above its 200-day average ›
The price is 10.9% above the 200-day simple moving average of $26.54.50-day average above the 200-day ›
The 50-day average ($27.90) is 5.1% above the 200-day average ($26.54), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 93% of its 52-week range, between $23.62 and $29.88.
PFE share price
Pick a period: each tab shows how far PFE has moved over it, to the last close.
Today's trading
Where PFE sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/5P/E below the sector median ›
The trailing P/E of 37.27 is 16.8% above the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 2.63 is 22.5% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $4.3B on revenue of $63.7B, a net margin of 6.8%.Beat estimates in most recent reports ›
PFE beat the EPS estimate in 8 of its last 8 reports.Pays a dividend ›
The trailing dividend yield is 5.85%, or $1.72 a share a year.
Key statistics
The headline figures for PFE.
As of October 16, 2026, PFE trades at $29.44, with a market value of $167.80B, a P/E ratio of 37.27 and a dividend yield of 5.85%.
What the numbers say
CleaRank Financial AI's reading of PFE's valuation, growth and risks.
At a trailing P/E of 37.27 on EPS of $0.79, Pfizer trades at a premium to the Healthcare sector median P/E of 31.9, and the price-to-sales ratio of 2.63 is below the sector median of 3.4. The valuation therefore rests on earnings recovery rather than on sales, since the market is paying up for profit that is still compressed.
Profitability is thin: the net profit margin is 6.80% and the return on equity is 5.01%, against a sector median ROE of 7.3. The operating margin of 27.88% shows the core business is more profitable than its net line, which points to heavy non-operating charges and interest costs. The debt-to-equity ratio is 0.74, equal to the sector median of 0.74, so leverage is in line with peers and does not add balance sheet risk on its own.
The prior three quarters beat: results reported May 5, 2026 came in at $0.75 versus $0.72 (4.17% surprise, +0.30% price move), results reported February 3, 2026 at $0.66 versus $0.57 (15.79% surprise, +3.92%), and results reported November 4, 2025 at $0.87 versus $0.63 (38.10% surprise, +1.28%).
The beat pattern is consistent across four straight quarters, but Wall Street expects the top line to shrink: current-quarter revenue growth is -13.6% and next-quarter growth is forecast at -4.00%. Earnings quality therefore depends on cost control and product mix rather than on top-line expansion.
Valuation is the most immediate risk: the stock is 3.20% above the $28.50 median analyst target and trades at 37.27 times earnings, so any earnings miss would likely compress the multiple quickly. Revenue risk is also material, since analysts forecast a 4.00% decline in next-year sales to $59.9B and a -4.00% revenue decline for the next quarter. Finally, the 14-day RSI of 68.31 and stochastic of 83.33 leave the stock vulnerable to a short-term pullback toward the 20-day EMA at $28.28 if momentum fades.
PFE against the Healthcare sector
How PFE compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (17% difference), suggesting fair market pricing relative to industry standards.
Return vs XLV: Since May 5, 2025, PFE has gained 23.3% against a gain of 28.3% for XLV.
Performance against XLV
PFE and the Healthcare sector fund over the same days.
Revenue and earnings
How much PFE sells, and how much of it becomes profit.
Revenue growth: Revenue fell 1.6% in FY2025 to $62.6B, from $63.6B a year earlier.
Profit margin: The net margin was 12.5% in FY2025, down from 12.7% the year before.
Profitable: PFE earned $7.8B in FY2025.
Earnings reality check
Did PFE beat what analysts expected, and how did the stock react?
Earnings record: PFE beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 1 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 4, 2026after close | $0.68 | $0.77 | +13.24% | +1.57% | +4.76% |
| May 5, 2026after close | $0.72 | $0.75 | +4.17% | +0.30% | -2.19% |
| Feb 3, 2026after close | $0.57 | $0.66 | +15.79% | +3.92% | +7.14% |
| Nov 4, 2025after close | $0.63 | $0.87 | +38.10% | +1.28% | +4.98% |
| Aug 5, 2025after close | $0.57 | $0.78 | +36.84% | -3.31% | -0.40% |
| Apr 29, 2025after close | $0.67 | $0.92 | +37.31% | +2.61% | -3.83% |
| Feb 4, 2025after close | $0.46 | $0.63 | +36.96% | +2.20% | -1.31% |
| Oct 29, 2024after close | $0.61 | $1.06 | +73.77% | +0.21% | -1.65% |
As of October 16, 2026, PFE has beaten the analyst EPS estimate in 8 of its last 8 reported quarters and fell in the first trading session after 1 of those beats; its latest report, on August 4, 2026, came in 13.24% above the estimate and the stock moved +1.57% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 68.3, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 68.3 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of PFE
The score, the reasoning behind it, and what could move the price next.
The 14-day RSI (Wilder, daily closes) reads 68.31, which indicates strong momentum that is approaching overbought territory without yet reaching it. The 14-day RSI and stochastic at 83.33 together point to a stretched short-term tape, and the CCI at 180.81 confirms the move is extended relative to recent prices.
Price is above the 50-day simple moving average at $27.90, the 200-day simple moving average at $26.54 and the 20-day EMA at $28.28, so all three levels now act as support. The MACD of 0.29 is positive, consistent with the bullish trend. The first resistance is the recent high near the current $29.44 price, and a pullback toward the 20-day EMA at $28.28 would be a normal reset within the trend, with the 50-day simple moving average at $27.90 as the next support below it.
Insider Open-Market Buying ›
Insiders are net buyers with $2.96M in purchases, led by Chairman and CEO an insider, which the insider verdict classifies as a moderate buy signal.
Source: SEC Form 4 Filings
Forecast Revenue Decline ›
Analysts expect revenue of $62.3B for the current year with 0.00% growth and $59.9B next year, a 4.00% decline, which challenges the earnings-led rally.
Source: Wall Street Consensus
- With the 14-day RSI (Wilder, daily closes) at 68.31 and the stochastic at 83.33, the stock is extended; a pullback toward the $28.28 20-day EMA would be a more favorable entry than the current $29.44 price.
- Set a stop-loss well below the $26.54 200-day simple moving average, since a close beneath that level would break the long-term uptrend and remove the main technical support.
Downside risks include a missed quarter that exposes the 37.27 P/E, a further downgrade (JP Morgan and Cantor Fitzgerald currently rate the stock Neutral), or a break below the 200-day simple moving average at $26.54. Competitors such as MRK, JNJ and ABBV set the benchmark for large-cap pharma valuation.
Technical indicators
Momentum and trend for PFE, from its daily closes.
As of October 16, 2026, with PFE at $29.44, its 14-day RSI is 68.3 (showing bullish momentum without being overbought), its 50-day simple moving average is $27.90 and its 200-day is $26.54.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What PFE moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, PFE's 1-year correlation of daily returns is +0.27 with S&P 500 (SPY), +0.15 with Nasdaq 100 (QQQ), +0.05 with Bitcoin (BTC) and +0.08 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
0/3Most analysts rate it a buy ›
10 of 28 analysts rate it a buy or strong buy, 16 a hold and 2 a sell.Median target above the price ›
The median 12-month target of $28.50 is 3.2% below the price.More buy ratings than three months ago ›
10 of 28 rate it a buy now, against 10 of 28 three months ago.
PFE Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 9, 2026 | JP Morgan | Maintains | Neutral |
| Oct 8, 2026 | Cantor Fitzgerald | Maintains | Neutral |
| Oct 6, 2026 | Scotiabank | Maintains | Sector Outperform |
| Sep 10, 2026 | HSBC | Maintains | Hold |
| Aug 7, 2026 | Guggenheim | Maintains | Buy |
| Jul 13, 2026 | BMO Capital | Maintains | Outperform |
As of October 16, 2026, 28 Wall Street analysts cover PFE: 10 rate it a buy or strong buy, 16 a hold and 2 a sell or strong sell. Their 12-month price targets range from $25.00 to $36.00, with a median of $28.50, 3.2% below the price of $29.44.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
PFE trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from PFE's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much PFE tends to move, against the market and on its own.
The long record
PFE's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/4Average daily move under 2% ›
The price has moved 1.06% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 57.4%, from December 2021 to April 2025; the price is still 36.3% below that peak.Most 1-year holds ended higher ›
58% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $14,956, against $42,525 in the S&P 500 (SPY).
PFE Drawdowns & Recovery
As of October 16, 2026, PFE's worst peak-to-trough fall over the last 10 years with dividends reinvested was -57.4% (December 2021 to April 2025); it is still 36.3% below that peak, and 58% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into PFE in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: PFE trailed the S&P 500 over this period: $14,956 against $42,525.
A $10,000 investment in PFE in October 2016 would be worth about $14,956 today with dividends reinvested, compared with about $42,525 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to PFE, and which have not.
Strongest month, November: an average of +4.35%, up in 8 of 10 years.
Weakest month, February: an average of -2.43%, up in 3 of 10 years.
This month, October: has averaged -0.18%, up in 3 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, PFE's strongest calendar month has been November (average +4.35%, up in 8 of 10 years) and its weakest February (average -2.43%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in PFE, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in PFE today could grow to about $13,265 by 2036 in the base case, with a 90th-percentile outcome near $35,356 and a 10th-percentile outcome around $4,977. The simulation models price only; at today's 5.85% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
PFE Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $32.96 for PFE by 2030 in the base case, from $29.44 today (1.1x over 4 years). The 10th-percentile path ends near $17.73. These are outcomes of a Monte Carlo simulation run on PFE's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $22.21 | $30.28 | $41.29 | |
| 2028 | $20.09 | $31.15 | $48.29 | |
| 2029 | $18.73 | $32.04 | $54.82 | |
| 2030 | $17.73 | $32.96 | $61.28 | |
| 2031 | $16.95 | $33.91 | $67.82 |
Method: a lognormal simulation of PFE's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
PFE insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $3.0M on the open market and sold $135K.
As of October 16, 2026, PFE insiders reported 2 open-market sales worth $135K and 3 open-market purchases worth $3.0M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 12, 2026 | Albert Bourla
Chief Executive Officer
|
Buy | 38.0K | $1.0M |
| Aug 5, 2026 | Jennifer B. Damico
Officer
|
Sell | 3.3K | $83.3K |
| Aug 5, 2026 | Ronald E Blaylock
Director
|
Buy | 39.2K | $998.8K |
| Aug 5, 2026 | Mortimer J. Buckley
Director
|
Buy | 37.6K | $960.4K |
| Jun 9, 2026 | Jennifer B. Damico
Officer
|
Sell | 2.0K | $51.4K |
| Mar 3, 2026 | Jennifer B. Damico
Officer
|
Grant | 21.7K | - |
| Feb 25, 2026 | Christoffel Boshoff
Officer
|
Grant | 13.4K | - |
| Feb 25, 2026 | Albert Bourla
Chief Executive Officer
|
Option | 491.6K | $16.6M |
| Feb 25, 2026 | Jennifer B. Damico
Officer
|
Option | 17.6K | $593.8K |
| Feb 25, 2026 | Lidia Ph.d. Fonseca
Officer
|
Option | 56.9K | $1.9M |
| Feb 25, 2026 | Douglas M Lankler
Officer
|
Option | 122.9K | $4.2M |
| Feb 25, 2026 | Michael Mcdermott
Officer
|
Option | 37.9K | $1.3M |
| Feb 25, 2026 | Payal Sahni
Officer
|
Option | 56.9K | $1.9M |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 16, 2026.